Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Opko Health, Inc. - Common Stock (NQ: OPK )

1.640 -0.020 (-1.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Opko Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 88 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Credit Suisse Group (NYSE:CS) was the largest, in terms of market cap... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Down 250 Points; OPKO Health Shares Plunge
Toward the end of trading Monday, the Dow traded down 1.84% to 33,636.46 while the NASDAQ fell 1.83% to 13,517.61. The S&P also fell, dropping, 1.98% to 4,310.71. The U.S. has... 
Via Benzinga
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
65 Biggest Movers From Yesterday
Gainers Exterran Corporation (NYSE: EXTN) shares surged 59.7% to close at $4.79 on Monday after the company said it would merge with Enerflex to create a premier integrated... 
Via Benzinga
Mid-Day Market Update: Dow Dips 1000 Points; Exterran Shares Jump
Midway through trading Monday, the Dow traded down 3.09% to 33,205.52 while the NASDAQ fell 4.56% to 13,141.60. The S&P also fell, dropping, 3.82% to 4,230.05. The U.S. has... 
Via Benzinga
54 Stocks Moving In Monday's Mid-Day Session
Gainers Exterran Corporation (NYSE: EXTN) shares jumped 52.4% to $4.5720 after the company said it would merge with Enerflex to create a premier integrated global provider of... 
Via Benzinga
Pfizer Dives After FDA Rejects Its OPKO-Partnered Rare Disease Treatment
Pfizer stock tumbled after the FDA rejected an OPKO-partnered drug. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 15.0% to $6.3 during Monday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Monday, Jan. 24, 2022: UL, SNAP, OPK, M, IBM
Today's 5 Stock Ideas: Unilever (UL) - Shares rose following a media report that hedge fund Trian Partners has built a stake in the company. Snap (SNAP) - Wedbush... 
Via Benzinga
28 Stocks Moving in Monday's Pre-Market Session
Gainers BT Brands, Inc. (NASDAQ: BTBD) shares rose 158% to $6.37 in pre-market trading after declining around 12% on Friday. Kohl's Corporation (NYSE: KSS) rose 28.4% to $60... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge
Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results... 
Via Benzinga
Pfizer - OPKO Health's Growth Hormone Deficiency Candidate Receives FDA Response Letter
The FDA has issued a Complete Response Letter (CRL) to Pfizer Inc (NYSE: PFE) and OPKO Health Inc's (NASDAQ: OPK) somatrogon. Somatrogon... 
Via Benzinga
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
From Pfizer Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 71.1% to $0.36 during Tuesday's regular session. Brickell Biotech's stock is trading at a volume of... 
Via Benzinga
Sema4 Strengthens AI-Driven Genomic, Clinical Data Platform With $623M GeneDx Acquisition
Sema4 Holdings Corp (NASDAQ: SMFR) has agreed to acquire OPKO Health Inc's (NASDAQ: OPK) wholly-owned subsidiary, GeneDx Inc, for approximately $623... 
Via Benzinga
OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference
From OPKO Health, Inc.
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
Opko Health Posts Data From COVID-19 Trial With Its Kidney Disease Treatment
OPKO Health Inc (NASDAQ: OPK) has announced preliminary topline results from its Phase 2 trial with Rayaldee to treat mild-to-moderate COVID-19. This study... 
Via Benzinga
Bulls Find Silver Lining Into the Close
While it isn't exactly a ringing endorsement that the market is heading higher, it is an indication that the Grinch hasn't entirely spoiled the fun. 
Via Talk Markets
63 Biggest Movers From Friday
Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Genfit (NASDAQ:GN... 
Via Benzinga
28 Stocks Moving In Friday's Mid-Day Session
Gainers Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor. X4 Pharmaceuticals, Inc... 
Via Benzinga
OPKO Health Q3 Earnings Ahead Of Expectations
OPKO Health Inc (NASDAQ: OPK) reported Q3 revenues were down 10% Y/Y to $385.8 million, beating the consensus of $302.27 million. Revenue from diagnostic services... 
Via Benzinga
Opko Health (OPK) Q3 2021 Earnings Call Transcript
OPK earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Bellerophon Therapeutics (NASDAQ: 
Via Benzinga
This Growth Hormone Drug Could Be a Boost For Pfizer
Pfizer and OPKO Health's human growth hormone drug, somatrogon, could be approved by the U.S. Food and Drug Administration next January. 
Via The Motley Fool
Exposures Product Safety
Pfizer's Growth Hormone Candidate FDA Review Pushed By 3 Months
Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag. The FDA has pushed back... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers eFFECTOR Therapeutics (NASDAQ: 
Via Benzinga
Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New York State, Announces ‘Back to School’ COVID-19 Testing Program
From Rite Aid Corporation
Via Business Wire
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.